LGND NASDAQ
Ligand Pharmaceuticals Incorporated
1W: +0.5%
1M: +5.6%
3M: -5.5%
YTD: +59.4%
1Y: +69.2%
3Y: +392.9%
5Y: +248.9%
$302.96
+0.22 (+0.07%)
Weekly Expected Move ±4.1%
$278
$290
$303
$315
$328
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.00
Neutral
0 bullish
1 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (61)
StoneX updates its best ideas list
Ligand Pharma a new Outperform at Barclays on biopharma royalty aggregation
Ligand, AvenCell ink financing deal worth up to $47M for CAR-T therapies
Ligand Acquires Royalty and Milestone Interest in Santen’s Ryjunea® from Sydnexis for $23 Million
Baird Financial Group Inc. Trims Holdings in Ligand Pharmaceuticals Incorporated $LGND
Allianz Asset Management GmbH Makes New Investment in Ligand Pharmaceuticals Incorporated $LGND
Handelsbanken Fonder AB Raises Stake in Ligand Pharmaceuticals Incorporated $LGND
Ligand (LGND) Q2 2026 Earnings Call Transcript
Ligand Pharmaceuticals Incorporated $LGND Shares Sold by Arrowstreet Capital Limited Partnership
Ashford Capital Management Inc. Has $41.44 Million Holdings in Ligand Pharmaceuticals Incorporated $LGND
Ligand resumed at buy at Citi with acquisition of XOMA Royalty
Ligand Completes Acquisition of XOMA Royalty, Creating a Portfolio of More than 200 Biopharmaceutical Royalty Assets
Agenus stock gains after private placement of up to $340M
3 Overlooked Stocks Positioned for the Next Market Rotation
Ligand Pharmaceuticals prices $625M convertible debt offering
Ligand prices proposed $550M convertible senior notes offering
Ligand Pharmaceuticals Director Unloads 2,501 Shares — Should You Be Concerned?
Ligand Announces 2026 Investor Day in New York City
A Ligand Pharmaceuticals (LGND) Insider Sold 5,000 Shares for $1.1 Million
Insider Unloading: Octavio Espinoza Sells Options, Realizes $307K
Ligand (LGND) Q1 2026 Earnings Call Transcript
Ligand Reports First Quarter 2026 Financial Results
Ligand Pharmaceuticals Q1 2026 Earnings Preview
Orchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing Agreement
Ligand to Participate in May Investor Conferences
Ligand Bets On Royalty Growth With XOMA Buyout Worth Over $700 Million
Ligand to buy XOMA Royalty for $39/share
Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator
Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand's Position as a Leading Biopharma Royalty Aggregator
Ligand Pharmaceuticals to buy XOMA Royalty in $740M all-cash deal: WSJ
B. Metzler seel. Sohn & Co. AG Invests $1.30 Million in Ligand Pharmaceuticals Incorporated $LGND
Ligand to Report First Quarter 2026 Financial Results on May 7, 2026
Assetmark Inc. Raises Holdings in Ligand Pharmaceuticals Incorporated $LGND
Chicago Capital LLC Has $106.15 Million Stake in Ligand Pharmaceuticals Incorporated $LGND
Aberdeen Group plc Lowers Stock Position in Ligand Pharmaceuticals Incorporated $LGND
Allspring Global Investments Holdings LLC Has $13.65 Million Position in Ligand Pharmaceuticals Incorporated $LGND
Insider Move: John L LaMattina Exercises Options, Realizing $185K At Ligand Pharmaceuticals
CLO Sells LGND 5,000 Shares for $1.0 Million
Ligand Pharma CFO Sells $688K in Stock as Shares Surge 80% This Past Year. Here's What to Know
Congress Asset Management Co. Sells 187,248 Shares of Ligand Pharmaceuticals Incorporated $LGND
Acuitas Investments LLC Trims Holdings in Ligand Pharmaceuticals Incorporated $LGND
Ligand Pharmaceuticals Is A Low-Risk Way To Bet On Biopharma Growth: Analyst
Ligand gains new Buy from BofA on high-margin, less risky narrative
This Ligand Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday
Rice Hall James Buys QuidelOrtho Stock
Rice Hall James Buys Stride Stock
Fisher Asset Management LLC Buys 2,860 Shares of Ligand Pharmaceuticals Incorporated $LGND
Citigroup Inc. Trims Stake in Ligand Pharmaceuticals Incorporated $LGND
Ligand to Participate in March Investor Conferences
Ligand outlines 23% CAGR royalty growth outlook through 2030 as royalty portfolio accelerates
Ligand Pharmaceuticals Incorporated (LGND) Q4 2025 Earnings Call Transcript
Ligand Pharmaceuticals Non-GAAP EPS of $2.02 beats by $0.52, revenue of $59.7M beats by $4.11M
Ligand Reports Fourth Quarter and Full Year 2025 Financial Results
Here are the major earnings before the open Thursday
Ligand Pharmaceuticals Q4 2025 Earnings Preview
Ligand to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
Ligand to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Acuitas Investments LLC Purchases 382,597 Shares of Ligand Pharmaceuticals Incorporated $LGND
Ligand Pharmaceuticals Incorporated $LGND Shares Sold by Chicago Capital LLC
Ligand Pharmaceuticals Incorporated (LGND) Analyst/Investor Day Transcript
Ligand Hosts 2025 Investor Day and Introduces 2026 Guidance